Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMBOL-Clinical: Allogeneic BM-MSCs for Severe Ocular Chemical Burns
NCT07329569Phase 2Not yet recruiting
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Mar 2026
- Primary completion
- Sep 2029
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of allogeneic bone marrow-derived mesenchymal stromal cells in ocular chemical burn, sponsored by Adolphe de Rothschild Foundation Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
ocular chemical burn
Beyond the preview
Go deeper on NCT07329569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07329569.